Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat

Neuropathol Appl Neurobiol. 2022 Apr;48(3):e12781. doi: 10.1111/nan.12781. Epub 2021 Dec 7.

Abstract

We report the neuropathological examination of a patient with Alzheimer's disease (AD) treated for 38 months with low doses of the BACE-1 inhibitor verubecestat. Brain examination showed small plaque size, reduced dystrophic neurites around plaques and reduced synaptic-associated Aβ compared with a group of age-matched untreated sporadic AD (SAD) cases. Our findings suggest that BACE-1 inhibition has an impact on synaptic soluble Aβ accumulation and neuritic derangement in AD.

Keywords: Alzheimer's disease; BACE-1; amyloid beta; amyloid plaques; synapse; verubecestat.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Alzheimer Disease* / pathology
  • Amyloid beta-Peptides / metabolism
  • Brain / pathology
  • Cyclic S-Oxides / therapeutic use
  • Humans
  • Plaque, Amyloid / drug therapy
  • Plaque, Amyloid / pathology
  • Thiadiazines* / therapeutic use

Substances

  • Amyloid beta-Peptides
  • Cyclic S-Oxides
  • Thiadiazines
  • verubecestat